FindTrial
Sign In

Using multi-omics to investigate intratumoral heterogeneity and driver genes in early-stage lung cancer

Using multi-omics to investigate intratumoral heterogeneity and driver genes in early-stage lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117196
Enrollment
Unknown
Registered
2026-01-21
Start date
2022-04-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Observation group:This study is an observational study and no intervention measures were applied to the subjects.

Sponsors

Department of Thoracic Surgery, Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Confirmed by surgery and pathology as a patient with non-small cell lung cancer; 2. Plan to remove pulmonary nodules; 3. Initial diagnosis, without any tumor related treatment; 4. Agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who have undergone bone marrow transplantation or cell transplantation; 3. There are other concurrent tumors; 4. Patients with tumor recurrence; 5. Patients who have received allogeneic blood transfusions within 6 months.

Design outcomes

Primary

MeasureTime frame
The number of differentially expressed genes and significant fold differences between tumor tissues at different pathological stages;—

Countries

China

Contacts

Public ContactJigang Dai, Hong Zheng

Department of Thoracic Surgery, Second Affiliated Hospital of Army Medical University

daijigang@tmmu.edu.cn+86 139 8312 2867

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026